EF4 data

The British company completed analysis of the second year of the Phase III trial, in which patients who had been on placebo were switched to EF4.

In the group that had continued the drug for the second year, scores improved on 24 of 28 parameters in the 12-to-24 month period. All three parameters that had not improved the first year did so in the second. ...